|
|
|
| Academic experience of professor Jiang Liangduo in the treatment of myositis ossificans progressiva |
| DENG Yaping1 WANG Lan1，2 LIANG Siling1 LI Shiqing1 |
1.Department of Emergency, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
2.Jiang Liangduo Famous Doctor Inheritance Workstation, Beijing 100700, China |
|
|
|
Abstract Myositis ossificans progressiva is a rare and serious crippling disease. It is mainly manifested in the formation of heterotopic bone, such as tendon, ligament, fascia, aponeurosis, striated muscle, etc. The pathophysiological mechanism has not been fully defined. At present, the study shows that the disease is related to the mutation of activin A receptor, and there is no specific and effective treatment. There is no relevant record of “myositis ossificans progressiva” in ancient books of traditional Chinese medicine. Modern doctors mostly classify this disease as “arthralgia” and mainly treat it by promoting blood circulation and removing blood stasis, relaxing muscles and activating collaterals. Professor Jiang Liangduo thinks that the pathogenesis of the disease is kidney deficiency and heat toxin accumulated in the blood. Therefore, the treatment is based on tonifying the kidney, clearing the blood and detoxifying the blood. At the same time, on the basis of traditional Chinese medicine treatment, combined with local low-dose radiotherapy, the effect is quite remarkable.
|
|
|
|
|
|
[1] Walczak BE，Johnson CN，Howe BM. Myositis ossificans [J]. Am Acad Orthop Surg，2015，23（10）：612-622.
[2] She DM，Zhang KQ. Fibrodysplasia ossificans progressiva in China [J]. Bone，2018，109：101-103.
[3] 包和婧，朱立新，杨联军，等.我国进行性骨化性肌炎104例文献分析[J].分子影像学杂志，2015，38（4）：365-368.
[4] Shore EM，Xu M，Feldman GJ，et al. A recurrent mutation in the BMP type Ⅰ receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva [J]. Nat Genet，2006，38（5）：525-527.
[5] Hatsell SJ，Idone V，Wolken DM，et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A [J]. Sci Transl Med，2015，7（303）：303ra137.
[6] Bauer AH，Bonham J，Gutierrez L，et al. Fibrodysplasia ossificans progressiva：a current review of imaging findings [J]. Skeletal Radiol，2018，47（8）：1043-1050.
[7] 袁晓霞.骨化性肌炎的影像学诊断[J].影像研究与医学应用，2017，1（14）：99-101.
[8] Gupta N，Pruthi A， Kumar S，et al. Fibrodysplasia ossificans progressiva—a rare genetic disorder and the role of technetium-99m methylene diphosphonate bone scan [J]. Indian J Nucl Med，2019，34（3）：209-212.
[9] 张斌青，李登宇，郭会利.SPECT/CT融合显像对骨化性肌炎的诊断增益价值[J].中国中医骨伤科杂志，2019，27（3）：73-75.
[10] 刘博文.高频超声诊断肱三头肌肌腱断裂伴骨化性肌炎临床分析[J].影像研究与医学应用，2018，2（21）：145-147.
[11] Raees-Karami SR，Jafarieh H，Ziyayi V，et al. Evaluation of 20 years experience of fibrodysplasia ossificans progressiva in Iran：lessons for early diagnosis and prevention [J]. Clin Rheumatol，2012，31（7）：1133-1137.
[12] 吴清木，齐树青，林顺新，等.进行性骨化性纤维组织结构不良症1例随访10年报告[J].中华骨质疏松和骨矿盐疾病杂志，2017，10（4）：382-385.
[13] Kaplan FS，Al Mukaddam M，Baujat G，et al. The medical management of fibrodysplasia ossificans progressiva：current treatment considerations [J]. Proc Intl Clin Council FOP，2019，1：1-111.
[14] 李莉，孟毅，李永亮.中医药治疗全身进行性骨化性肌炎1例[J].中医杂志，2014，55（18）：1619-1620.
[15] 李明哲.针灸结合中药熏洗治疗肘关节骨化性肌炎临床疗效观察[J].光明中医，2015，30（10）：2155-2156.
[16] 吴延义，李洁林，丁小新.五虎消瘀散治疗肘关节创伤性骨化性肌炎临床疗效观察[J].中医药临床杂志，2014， 26（10）：1057-1058.
[17] 梁国光.口服软坚汤配合中药烫疗治疗成人肘关节骨化性肌炎的疗效观察[J].中医临床研究，2018，10（27）：65-67.
[18] 张聪，张振，晏小华.关节松动联合针药治疗强力牵拉后膝关节骨化性肌炎疗效观察[J].浙江中西医结合杂志，2018，28（8）：689-691.
[19] 罗岚，曾文璧.毫火针联合手法治疗肘关节早期创伤性骨化性肌炎临床观察[J].中国民族民间医药，2018，27（6）：94-95，98.
[20] 陈锐，郭珊成.塞来昔布联合局部放疗预防肘关节骨化性肌炎的早期效果观察[J].第三军医大学学报，2015， 37（24）：2468-2471.
[21] Pacifici M. Acquired and congenital forms of heterotopic ossification：new pathogenic insights and therapeutic opportunities [J]. Curr Opin Pharmacol，2018，40：51-58.
[22] 赵宁，曹林忠，慕向前，等.创伤性骨化性肌炎的中西医防治进展[J].甘肃中医药大学学报，2016，33（5）：81-83. |
|
|
|
